Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Depiction of Prostate Cancer Treatment Alternatives in Greece

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00733213
Recruitment Status : Completed
First Posted : August 12, 2008
Last Update Posted : October 14, 2009
Sponsor:
Information provided by:
AstraZeneca

Tracking Information
First Submitted Date August 8, 2008
First Posted Date August 12, 2008
Last Update Posted Date October 14, 2009
Study Start Date January 2008
Primary Completion Date Not Provided
Current Primary Outcome Measures
 (submitted: August 11, 2008)
Percentage of patients treated by each treatment alternative. [ Time Frame: Between 2002 - 2008 ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: August 11, 2008)
To depict sociodemographic characteristics and comorbidities. [ Time Frame: Between 2002 - 2008 ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Depiction of Prostate Cancer Treatment Alternatives in Greece
Official Title Depiction of Prostate Cancer Treatment Alternatives in Greece
Brief Summary

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.

  • Target Group: Patients with locally advanced or metastatic prostate cancer.
  • The first 10 consecutive patients records that meet the entry criteria.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer
Condition Locally Advanced or Metastatic Prostate Cancer.
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Estimated Enrollment
 (submitted: August 11, 2008)
310
Original Estimated Enrollment Same as current
Actual Study Completion Date March 2009
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
  • Patients that received Hormonal therapy.

Exclusion Criteria:

  • Males that are aged less than 18 years
Sex/Gender
Sexes Eligible for Study: Male
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Greece
Removed Location Countries  
 
Administrative Information
NCT Number NCT00733213
Other Study ID Numbers NIS-OGR-DUM-2007/1
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director, AstraZeneca, SA Greece
Study Sponsor AstraZeneca
Collaborators Not Provided
Investigators
Study Director: Panagiotis Pontikis, MD AstraZeneca Greece
PRS Account AstraZeneca
Verification Date October 2009